Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-07
2011-06-07
Spector, Lorraine (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007950, C436S501000
Reexamination Certificate
active
07955804
ABSTRACT:
A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.
REFERENCES:
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: 2005/0255484 (2005-11-01), Valkirs et al.
Gok et al., Clinical Chemica Acta, 338(1-2):33-43, Dec. 2003.
Wilson et al., FASEB, 14(5):791-796, 2000.
Ishii, J. et al., Clin. Chem. 43:1372-1378, 1997.
[abstract only] Tsuji, R. et al., Int. J. Cardiol. 41:209-217, 1993.
Glatz, J. F. et al., Br. Heart J. 71:135-140, 1994.
Hayashida et al., Jpn Circ J, 64:18-22, Jan. 2000.
Ramaswamy et al., Pediatric Neurology, 40(3):215-226, Mar. 2009.
Vaagenes P, Urdal P, Melvoll R, Valnes K: Enzyme level changes in the cerebrospinal fluid of patients with acute stroke. Arch Neurol 1986;43:357-362.
Matias-Guiu J, Martinez-Vazquez J, Ruibal A, Colomer R, Boada M, Codina A: Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke. Acta Neurol Scand 1986;73:461-465.
Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Pahlman S: S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-918.
Hochstrasser DFMerril CR: ‘Catalysts’ for polyacrylamide gel polymerization and detection of proteins by silver staining. Appl Theor Electrophor 1988;1:35-40.
Lampl Y, Paniri Y, Eshel Y, Sarova-Pinhas I: Cerebrospinal fluid lactate dehydrogenase levels in early stroke and transient ischemic attacks. Stroke 1990;21:854-857.
Cunningham RT, Young IS, Winder J, O'Kane MJ, McKinstry S, Johnston CF, Dolan OM, Hawkins SA, Buchanan KD: Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest 1991;21:497-500.
Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis 1992;13:992-1001.
Watson MAScott MG: Clinical utility of biochemical analysis of cerebrospinal fluid. Clin Chem 1995;41:343-360.
Appel RD, Palagi PM, Walther D, Vargas JR, Sanchez JC, Ravier F, Pasquali C, Hochstrasser DF: Melanie II—a third-generation software package for analysis of two-dimensional electrophoresis images: I. Features and user interface. Electrophoresis 1997;18:2724-2734.
Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ: Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31:2670-2677.
Sanchez J-C, Chiappe D, Converset V, Hoogland C, Binz P-A, Paesano S, Appel RD, Wang S, Sennitt M, Nolan A, Cawthorne MA, Hochstrasser DF: The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics 2001;1:136-163.
Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Ciesielczyk B, Cepek L, Bahn E, Ratzka P, Prange H, Otto M: Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol 2002;47:45-51.
N. Turck et al., “GSTP-1 and UFD-1 as Early Blood Markers of Acute Stroke,” Eurostroke (2006).
A. Hainard et al., “A Combined CXCL10, CXCL8 and H-FABP Panel for the Staging of Human African Trypanosomiasis Patients,” PLOS 3(6):e459 (2009).
Turck et al., “A multiparameter panel method for outcome prediction following aneurismal subarachnoid hemorrhage” Intensive Care Med (Sep. 17, 2009).
Zimmerman et al., “Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study” MCP Papers in Press (Manuscript M300066-MCP200) (Oct. 26, 2003).
Allard et al., “PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the early Diagnosis of Stroke” Clinical Chemistry 51:11 (2005).
Turck et al, “Blood GST-π Predicts Stroke Severity and Outcome”, unpublished manuscript prepared Dec. 2009, in Geneva, Switzerland.
Allard Laure
Hochstrasser Denis F.
Lescuyer Pierre
Sanchez Jean-Charles
Arent & Fox LLP
Electrophoretics Limited
MacFarlane Stacey
Spector Lorraine
LandOfFree
Diagnostic method for brain damage-related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic method for brain damage-related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic method for brain damage-related disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688099